Elicio Therapeutics’ ELI-002 2P cancer vaccine shows promising survival benefits in pancreatic and colorectal cancer patients, enhancing immune responses.

administrator
Elicio Therapeutics’ ELI-002 2P cancer vaccine shows promising survival benefits in pancreatic and colorectal cancer patients, enhancing immune responses.